FAQ Video ModulesFAQ Video Modules

FAQ: Biomarkers: The Non-Invasive Future of HCC Detection

February 2026

FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications

February 2026

FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?

February 2026

FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?

January 2026

FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?

January 2026

FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?

January 2026

FAQ: What Are the Functional and Prognostic Differences Between Fibrosis F3 and F4 Patients? How Are These Patients Managed Differently?

December 2025

FAQ: How Do You Explain Remission To A Patient?

November 2025

APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?

November 2025

FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?

October 2025

FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?

October 2025

APP Insight: Conducting Meaningful Conversations to Assess Therapy Impact

October 2025

APP Insight: Evaluating Time to Response and Treatment Effectiveness

September 2025

APP Insight: Why Is It Important to Let Patients Know There Are Different Options for Treatment?

September 2025

What Is the Difference Between CIC and IBS-C?

July 2025

APP Insight: Discussing Exercise as a Complement to IBS-C Treatment

July 2025

FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?

July 2025

APP Insight: Provide Diagnostic Tips for IBS-C

July 2025

Using the Bristol Stool Scale to Measure Response to Treatment

July 2025

FAQ: What Are the Main Causes of IBS, and How Does the Disease Progress Over Time?

July 2025

sectionimg

dotimg

Download the app and start using it now

Download on the App Store

GET IT ON Google Play